Anteris Technologies Global (NASDAQ:AVR) Releases Earnings Results, Beats Expectations By $0.03 EPS

Anteris Technologies Global (NASDAQ:AVR) issued its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03, FiscalAI reports. Anteris Technologies Global had a negative net margin of 4,637.48% and a negative return on equity of 61.24%. The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $2.75 million.

Anteris Technologies Global Stock Performance

Shares of AVR traded down $0.05 on Thursday, hitting $6.15. 154,954 shares of the stock traded hands, compared to its average volume of 1,154,347. The company has a market capitalization of $599.87 million, a PE ratio of -3.83 and a beta of 2.02. The business has a 50 day simple moving average of $7.08 and a 200 day simple moving average of $7.39. Anteris Technologies Global has a one year low of $3.30 and a one year high of $11.06.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AVR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays raised Anteris Technologies Global to a “hold” rating in a research report on Wednesday, October 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $14.00.

Insiders Place Their Bets

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were acquired at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the transaction, the insider owned 12,778,380 shares of the company’s stock, valued at $95,965,633.80. The trade was a 5.35% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have purchased 1,554,730 shares of company stock valued at $11,694,513. 4.50% of the stock is owned by insiders.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.